UNSPSC 51281635: Arbekacin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula C22H44N6O10.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7395HZ992, chemically known as d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1-4))-n-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (s)-, sulfate (salt) but more generally known as arbekacin sulfate, which bears US NIH Compound Identifier 175989.

UNSPSC 51281635 Arbekacin sulfate, a Commodity code, shows limited relevance to recent state and local procurement activity. The code designates a specific aminoglycoside antibiotic pharmaceutical, yet the most recent opportunities tagged under it do not reflect purchases of arbekacin itself. Instead, state and local bodies have posted solicitations for naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, direct-to-manufacturer prescription programs, and emergency medical and first aid supplies for fire rescue operations. These solicitations span health departments, state pharmacy benefit programs, cooperative purchasing alliances, and municipal emergency services — issuing bodies that would theoretically procure specialty pharmaceuticals through established channels, but the recent activity shows no specific demand signal for arbekacin or other aminoglycosides at the commodity level.

Geographic representation in the recent-opportunities block includes Florida (Seminole County), Texas (HHS Commission), Minnesota (MMCAP cooperative, serving multiple states including Oregon), and Florida again (City of Tampa). The mix reflects state health agencies, county public health departments, municipal fire departments, and multistate cooperative purchasing vehicles. A representative opportunity is Seminole County's IFB60459723LAS, an invitation for bid posted June 30, 2026, with response due July 26, 2023, seeking naloxone and drug deactivation systems for community health initiatives. Another is MMCAP's RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers serving state and local facilities across multiple jurisdictions. The code shows no traceable recent procurement activity specifically for arbekacin or comparable specialty injectable antibiotics; the tagging appears to reflect a classification mismatch rather than active demand under this commodity code.